Ascendis Pharma A/S (NasdaqGS: ASND)
Health Care · Biotechnology · DK
$227.50
-0.75% today · +6.7% 1Y
Ascendis Pharma A/S (NasdaqGS: ASND) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.05B and employs 1,189 people.
Over the last twelve months the share price has gained 6.7%, trading between 203.80 and 282.15.
Tweenvest scores Ascendis Pharma A/S across four factors: quality 31/100, value 41/100, growth 100/100. Its strongest factor is growth.
ASND price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.05B
- Revenue (TTM)
- $1.20B
- P/E
- 17.13
- EPS
- 11.72
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $282.15
- 52-week low
- $203.80
- Avg volume (3M)
- —
- Shares outstanding
- 65.67M
- Employees
- 1,189
- Next earnings
- —
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
- ISIN
- DK0060615755
- Founded
- 2006
- Listed since
- Jan 28, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Insmed IncorporatedNasdaqGS: INSM | $21.97B | $99.55 | -1.04% |
| Genmab A/SCPSE: GMAB | $21.89B | Dkr2,487.00 | +1.72% |
| Innovent Biologics, Inc.SEHK: 1801 | $20.55B | HK$92.65 | +0.05% |
| PharmaEssentia CorporationTWSE: 6446 | $15.49B | NT$1,195.00 | +2.58% |
| Swedish Orphan Biovitrum AB (publ)OM: SOBI | $14.91B | Skr432.60 | +0.98% |
| Exelixis, Inc.NasdaqGS: EXEL | $14.83B | $60.70 | +1.39% |
| Neurocrine Biosciences, Inc.NasdaqGS: NBIX | $14.48B | $141.71 | -0.51% |
| Summit Therapeutics Inc.NasdaqGM: SMMT | $14.07B | $17.38 | -1.22% |
Figures last refreshed Oct 11, 2026.